Skip to main content
Premium Trial:

Request an Annual Quote

Gordon Brandt, Steven Quay

Premium
Nastech Pharmaceutical has promoted Gordon Brandt to the position of president. He was formerly executive vice president of clinical research and medical affairs.
 
In his new role, Brandt takes over for former President Steven Quay, who will continue to serve as Nastech’s chairman and CEO.
 
"This move … allows me to increase my efforts on establishing [spinout] MDRNA as an independent company concentrating on the development of RNA-based therapeutics, which we believe will eventually provide greater focus for both companies,” Quay said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.